The online version of the original chapter can be found under DOI 10.1007/978-1-4939-1393-0_40
You have full access to this open access chapter, Download chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Erratum to:
Chapter 40 in: M. Andreeff (ed.), Targeted Therapy of Acute Myeloid Leukemia,
Current Cancer Research, DOI 10.1007/978-1-4939-1393-0_40
The Publisher regrets that in chapter 40, figure 40.1 is incorrect. The correct figure is given below.
The antileukemic benefit of KIR mismatch. NK cells in a donor who is heterozygous for HLA-C with respect to KIR ligands (having both a Group C1 allele that interacts with KIR2DL2 and a Group C2 allele that interacts with KIR2DL1) will be skewed toward no activation when receiving both inhibitory signals. However, when the NK cells are transferred to a recipient who is homozygous at HLA-C (e.g., HLA-C alleles are Group C1) the NK cells will lack the inhibitory signal through KIR2DL1, further tipping the balance toward activation when encountering tumor cells that also express activating ligands
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag New York
About this chapter
Cite this chapter
Lee, D., Cooper, L., Shpall, E. (2015). Erratum to: NK-Cell Immunotherapy for AML. In: Andreeff, M. (eds) Targeted Therapy of Acute Myeloid Leukemia. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1393-0_44
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1393-0_44
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1392-3
Online ISBN: 978-1-4939-1393-0
eBook Packages: MedicineMedicine (R0)